[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587437":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":34,"locations":35,"responsibleParty":58,"collaborators":62,"id":75,"slug":34,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":34,"eligibilityCriteria":80,"healthyVolunteers":76,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":34,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":34,"overallStatus":37,"whyStopped":34,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Chinese PLA General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Venetoclax Combined With CACAG Regimen","EXPERIMENTAL","The CACAG+Venetoclax regimen has a total treatment period of 1 week, with a treatment cycle every 4 weeks, and a total of 1 course of treatment.\n\nChidamide: 30 mg, twice a week, for a total of 2 administrations; Azacitidine: 75 mg\u002Fm\\^2 from day 1 to day 7; Cytarabine (Ara-C): 75-100 mg\u002Fm\\^2 every 12 hours from day 1 to day 7; Aclarubicin: 20 mg\u002Fm\\^2 on days 1, 3, and 5; Recombinant human granulocyte colony-stimulating factor (G-CSF): 300 μg\u002Fday, continued until neutrophil recovery and white blood cell count is ≥20,000\u002FμL; Venetoclax: 100 mg on day 1, 200 mg on day 2, 400 mg from day 3 to day 14, when used in combination with azole drugs, the dosage is reduced to 100 mg\u002Fday.",[13],"Drug: Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor",{"label":15,"type":16,"description":17,"interventionNames":18},"\"3+7\" Regimen","ACTIVE_COMPARATOR","Idarubicin+cytarabine(IA) regimen or daunorubicin+cytarabine(DA) regimen for newly diagnosed AML.Recipients were randomized and those entering this group received IA or DA induction chemotherapy. With the IA regimen,recipients received idarubicin(8-10 mg\u002Fm2) for three days and cytarabine(75-100 mg\u002Fm2, every 12 hrs) for seven days. With the DA regimen,recipients received daunorubicin(60 mg\u002Fm2)for three days and cytarabine(75-100 mg\u002Fm2,every 12 hrs)for seven days.",[19],"Drug: \"3+7\"",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor","Azacytidine (75 mg\u002Fm2\u002Fday, days 1 to 7). Cytarabine (75-100 mg\u002Fm2 bid, days 1 to 5). Aclacinomycin(20 mg\u002Fday, days 1,3,5). Chidamide (30 mg\u002Fday , days 1,4,8,11). Venetoclax (400 mg\u002Fday, days 1 to 14,Combined with posaconazole reduced to 100 mg\u002Fday,Combined with voriconazole reduced to 200 mg\u002Fday ).\n\nGranulocyte colony-stimulating factor (300 μg\u002Fday, day 0 until agranulocytosis recovery)",[9],[27],"CACAG+VEN",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"\"3+7\"","IA regimen:\n\nIdarubicin (8-10 mg\u002Fm2) for 3 days . Cytarabine (75-100mg\u002Fm2, every 12 hrs) for 7 days.\n\nDA regimen:\n\nDaunorubicin(60 mg\u002Fm2) for 3 days. Cytarabine (75-100mg\u002Fm2, every 12 hrs) for 7 days.",[15],[33],"IA or DA",null,[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Beijing","Beijing Municipality","100853","China",{"type":43,"coordinates":44},"Point",[45,46],116.39723,39.9075,{"lat":46,"lon":45},[49,54],{"name":50,"role":51,"phone":52,"phoneExt":34,"email":53},"Daihong Liu, doctor","CONTACT","86-13681171597","daihongrm@163.com",{"name":55,"role":51,"phone":56,"phoneExt":34,"email":57},"Qingyang Liu, doctor","+8617808071170","1074745197@qq.com",{"type":59,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":34,"oldOrganization":34},"PRINCIPAL_INVESTIGATOR","Daihong Liu","Director of the Department of Hematology",[63,65,67,69,71,73],{"name":64,"class":6},"First Affiliated Hospital of Harbin Medical University",{"name":66,"class":6},"Yantai Yuhuangding Hospital",{"name":68,"class":6},"The General Hospital of Western Theater Command",{"name":70,"class":6},"940 Hospital of the People's Liberation Army Joint Logistic Support Force",{"name":72,"class":6},"960th Hospital of Joint Logistics Support Force of People's Liberation Army of China",{"name":74,"class":6},"Jining First People's Hospital","100587437",false,"NCT06928376","A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid\u002FHigh-Risk AML Patients","A Multicenter, Prospective, Randomized Controlled Study of the Standard \"3+7\" Regimen Versus Venetoclax Combined With CACAG Regimen in Newly Diagnosed Adult Patients With Intermediate- and High-risk Acute Myeloid Leukemia","Inclusion Criteria:\n\nAge 14 to 75 years (no gender limitation) Newly diagnosed with intermediate- or high-risk AML (excluding M3) Liver function: ALT and AST ≤ 2.5 times upper limit of normal; bilirubin ≤ 2 times upper limit of normal Renal function: creatinine ≤ upper limit of normal No uncontrolled infections, organ dysfunction, or severe mental illness ECOG performance status score of 0-2 and predicted survival ≥ 4 months No severe allergic constitution\n\nExclusion Criteria:\n\nAllergy or contraindication to the study drug Pregnant or breastfeeding female patients Known history of alcohol or drug addiction (due to potential non-compliance) Mental illness or conditions preventing protocol compliance Less than 6 weeks after major organ surgery Liver function: ALT and AST \\> 2.5 times upper limit of normal; bilirubin \\> 2 times upper limit of normal Renal function: creatinine \\> upper limit of normal Deemed unsuitable for the clinical trial (poor compliance, substance abuse, etc.)\n\n\\-","ALL","14 Years","75 Years",{"count":85,"type":86},160,"ESTIMATED","INTERVENTIONAL",[89],"PHASE2","The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional \"3+7\" regimen in the treatment of newly diagnosed intermediate- or high-risk acute myeloid leukemia (AML).",[92,93],"Acute Myeloid Leukemia","First Line Therapy","2026-05-04",{"date":96,"type":97},"2026-05-08","ACTUAL",{"date":99,"type":97},"2024-04-18",{"date":101,"type":86},"2026-09-01",{"name":5,"class":6},1]